1<!DOCTYPE html> 2<html lang="en"> 3 4<head> 5 <!-- Google tag (gtag.js) -->
vendor: 68 bytes, lines 5-6
5 6 <script async src="https://www.googletagmanager.com/gtag/js?id=
6G-VQ4MJTJYQ5
vendor: 12 bytes, line 6
6"></script>
6<script>
vendor: 127 bytes, line 6
6window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', '
6G-VQ4MJTJYQ5
vendor: 4 bytes, line 6
6');
6</script>
6 7 <meta name="viewport" content="width=device-width, initial-scale=1" /> 8 <meta http-equiv="content-type" content="text/html; charset=utf-8" /> 9 <link rel="icon" type="image/png" href="https://magnusmedclub.com/assets-front/images/favicon.png" /> 10 <!-- Document title --> 11 <title>About Magnus Med Club | Magnus Med Club LLC | Ohio, USA</title> 12 <meta name="keywords" content="Magnus med club, magnus med club llc, magnus med, open access publisher, magnus med club journals, magnus medical journals, magnus clinical journals, mmc"/> 13 <meta name="description" content="Magnus Med Club LLC incorporated in ohio, usa offers open access publications having free access to magnus med club journals in medical and clinical domains."/> 14 <!-- Stylesheets & Fonts --> 15 <link href="https://fonts.googleapis.com/css?family=Montserrat:100,100i,200,200i,300,300i,400,400i,500,500i,600,600i,700,700i,800,800i,900,900i" rel="stylesheet"> 16 17 18 <!-- ========== Start Stylesheet ========== --> 19 <link href="https://magnusmedclub.com/assets-front/css/bootstrap.min.css" rel="stylesheet" /> 20 <link href="https://magnusmedclub.com/assets-front/css/font-awesome.min.css" rel="stylesheet" /> 21 22 <link href="https://magnusmedclub.com/assets-front/css/style.css" rel="stylesheet"> 23 <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css"> 24 25 <style> 26 .border8 { 27 border: 3px #000 solid; 28 } 29 </style> 30 31<!-- Schema Code -->
32<script type="application/ld+json"> 33 34{ 35 36 "@context": "https://schema.org", 37 38 "@type": "Organization", 39 40 "name": "Magnus Med Club LLC", 41 42 "alternateName": "Magnus Med", 43 44 "url": "https://www.magnusmedclub.com/", 45 46 "logo": "https://www.magnusmedclub.com/assets-front/images/mmc_logo.png", 47 48 "sameAs": [ 49 50 "https://www.facebook.com/MagnusMedClubLLC/", 51 52 "https://twitter.com/MagnusMedClub" 53 54 ] 55 56} 57 58</script>
58 59 60 61</head> 62<body class="no-page-loader"> 63 <!-- Wrapper --> 64 65<div class="topbar"> 66 <div class="container"> 67 <div class="row"> 68 <div class="col-md-6 col-sm-6 col-xs-12"> 69 <div class="topbarlists"> 70 <ul> 71 72<li><a href="https://magnusmedclub.com/about-us" title="About Us">About</a></li> 73 <li><a href="https://magnusmedclub.com/instructions" title="Instructions">Instructions</a></li> 74 <li><a href="https://magnusmedclub.com/contact-us" title="Contact us">Contact us</a></li> 75 </ul> 76 </div> 77 </div> 78 79 <div class="col-md-6 col-sm-6 col-xs-12"> 80 <div class="socialicons"> 81 <a href="https://www.facebook.com" target="_blank" title="Face Book" class="fa fa-facebook"></a> 82 <a href="https://x.com/magnus_med1203" target="_blank" title="Twitter"class="fa fa-twitter"></a> 83 <!-- <div class="social"> 84 85 </div> --> 86 </div> 87 </div> 88 </div> 89 </div> 90 </div> 91 <!-- LOGO TEXT --> 92 93 94<div class="logo"> 95 <div class="container"> 96 <a href="https://magnusmedclub.com/"> <img src="https://magnusmedclub.com/assets-front/images/mmc_logo.png"> </a> 97 <!-- <a href="https://magnusmedclub.com/" title="MAGNUS MED CLUB"> 98 <h1>MAGNUS MED CLUB</h1> 99 </a> --> 100 101 </div> 102 </div> <!-- end: LOGO TEXT --> 103 <header id="header" class="header header-transparent nav-border"> 104 <!-- Start Navigation --> 105 <nav class="navbar navbar-default navbar-sticky bootsnav"> 106 <div class="container"> 107 <!-- Start Header Navigation --> 108 <div class="navbar-header"> 109 <button type="button" class="navbar-toggle" data-toggle="collapse" class="navbar-toggle navbar-toggler ml-auto" data-target="#navbar-menu"> 110 <i class="fa fa-bars"></i> 111 </button> 112 113 </div> 114 <!-- End Header Navigation --> 115 <!-- Collect the nav links, forms, and other content for toggling --> 116 <div class="collapse navbar-collapse" id="navbar-menu"> 117 <ul class="nav navbar-nav navbar-left" data-in="fadeInDown" data-out="fadeOutUp"> 118 119 120 <li class=""> 121 <a href="https://magnusmedclub.com/home" target="" title="Home">Home</a> 122 123 </li> 124 125 <li class=" active"> 126 <a href="https://magnusmedclub.com/about-us" target="" title="About Us">About Us</a> 127 128 </li> 129 130 <li class=""> 131 <a href="https://magnusmedclub.com/journals" target="" title="Journals">Journals</a> 132 133 </li> 134 135 <li class=""> 136 <a href="https://magnusmedclub.com/submit-manuscript" target="" title="Submit Manuscript">Submit Manuscript</a> 137 138 </li> 139 140 <li class=""> 141 <a href="https://magnusmedclub.com/instructions" target="" title="Instructions">Instructions</a> 142 143 </li> 144 145 <li class=""> 146 <a href="https://magnusmedclub.com/contact-us" target="" title="Contact us">Contact us</a> 147 148 </li> 149 150 151 152 153 </ul> 154 </div><!-- /.navbar-collapse --> 155 </div> 156 </nav> 157 <!-- End Navigation --> 158 </header> 159 160 161 162 163 164 165 166 167 <!--END: HEADER--> 168 169 170 171 <!-- container --> 172 173 <div class="container"> 174 <div class="row m-t-20 m-b-20"> 175 <!-- Left section --> 176 <div class="col-md-9"> 177 178 179 <!-- articles start --> 180 181 <div class="journalarticlesheading"> 182 <h3>About Us</h3> 183 </div> 184 185 186 <div class="r-mid-box p-t-20"> 187 188 <div class="row"> 189 <div class="col-md-12"> 190 <p>Magnus Med Club (MMC) helps researchers to publish new discoveries in the various fields of research which leads to the development of the scientific community. Our journals are open access and constantly updated to keep the knowledge flowing. Open Access to scientific discoveries and ideas is an approach to propagate knowledge worldwide.</p> 191 192<h4>Who We Are</h4> 193 194<p>We are a team committed to present innovative research work. Magnus Med Club wants to provide the quality end of research papers to scientists, researchers in order to maintain the standards led by the publication ethics.</p> 195 196<h4>Vision</h4> 197 198<p>We aim to provide the best literature for the readers among the other publications. We utilize world-class technology, resources to maintain the high-end quality platform for the authors.</p> 199 200<h4>Mission</h4> 201 202<p>Our Mission is to promote research, create Value-based Knowledge and best global practices in sectors of the scientific field. Magnus Med Club anticipates standards to bring excellent quality journals in all fields.
202</p> 203 <div class="row m-t-40"> 204 205 </div> 206 </div> 207 </div> 208 209 210 211 <div class="journalarticlesheading"> 212 <h3>Articles </h3> 213 </div> 214 <div class="row"> 215 216 217 <div class="col-md-6"> 218 <div class="journalarticles fix_height"> 219 <div class="btn btn-sm btn-default m-b-10">Research Article</div> 220 221 <a href="https://www.oncogen.org/full-text/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells" target="_blank" title="CRISPR/Cas9-based Editing of CDK4, p107, and TGFβ1 in Human Breast and Lung Cancer Cells"><h3>CRISPR/Cas9-based Editing of CDK4, p107, and TGFβ1 in Human Breast and Lung Cancer Cells</h3></a> 222 223 <p> 224 Hussein Sabit<sup>1*</sup>, Doha Alaa<sup>2</sup>, [....] 225 </p> 226 <ul class="infolinks"> 227 228 <li><a href="https://www.oncogen.org/full-text/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells" target="_blank" title="CRISPR/Cas9-based Editing of CDK4, p107, and TGFβ1 in Human Breast and Lung Cancer Cells"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 229 230 231 232 <li> 233 <a href="https://www.oncogen.org/full-text/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells" target="_blank" title="CRISPR/Cas9-based Editing of CDK4, p107, and TGFβ1 in Human Breast and Lung Cancer Cells" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 234 </li> 235 236 237 238 239 </ul> 240 </div> 241 </div> 242 <div class="col-md-6"> 243 <div class="journalarticles fix_height"> 244 <div class="btn btn-sm btn-default m-b-10">Research Article</div> 245 246 <a href="https://www.oncogen.org/full-text/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy" target="_blank" title="Palliative Systemic Treatment Of Advanced Merkel Cell Carcinoma In The Pre-Immunotherapy Era: A Retrospective, Single-Center Analysis Of Patients With An Orphan Neuroendocrine Malignancy"><h3>Palliative Systemic Treatment Of Advanced Merkel Cell Carcinoma In The Pre-Immunotherapy Era: A Retrospective, Single-Center Analysis Of Patients With An Orphan Neuroendocrine Malignancy</h3></a> 247 248 <p> 249 Patrick Schöffski<sup>*</sup>, Gitte Moors, P [....] 250 </p> 251 <ul class="infolinks"> 252 253 <li><a href="https://www.oncogen.org/full-text/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy" target="_blank" title="Palliative Systemic Treatment Of Advanced Merkel Cell Carcinoma In The Pre-Immunotherapy Era: A Retrospective, Single-Center Analysis Of Patients With An Orphan Neuroendocrine Malignancy"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 254 255 256 257 <li> 258 <a href="https://www.oncogen.org/full-text/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy" target="_blank" title="Palliative Systemic Treatment Of Advanced Merkel Cell Carcinoma In The Pre-Immunotherapy Era: A Retrospective, Single-Center Analysis Of Patients With An Orphan Neuroendocrine Malignancy" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 259 </li> 260 261 262 263 264 </ul> 265 </div> 266 </div> 267 <div class="col-md-6"> 268 <div class="journalarticles fix_height"> 269 <div class="btn btn-sm btn-default m-b-10">Mini Review</div> 270 271 <a href="https://www.oncogen.org/full-text/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer" target="_blank" title="The Suppression Of Prolactin Is Required For The Treatment Of Advanced Prostate Cancer"><h3>The Suppression Of Prolactin Is Required For The Treatment Of Advanced Prostate Cancer</h3></a> 272 273 <p> 274 Leslie C Costello</p> 275 276 </p> 277 <ul class="infolinks"> 278 279 <li><a href="https://www.oncogen.org/full-text/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer" target="_blank" title="The Suppression Of Prolactin Is Required For The Treatment Of Advanced Prostate Cancer"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 280 281 282 283 <li> 284 <a href="https://www.oncogen.org/full-text/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer" target="_blank" title="The Suppression Of Prolactin Is Required For The Treatment Of Advanced Prostate Cancer" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 285 </li> 286 287 288 289 290 </ul> 291 </div> 292 </div> 293 <div class="col-md-6"> 294 <div class="journalarticles fix_height"> 295 <div class="btn btn-sm btn-default m-b-10">
295Review Article</div> 296 297 <a href="https://www.oncogen.org/full-text/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview" target="_blank" title="Post-Translational Modifications (PTMs), From A Cancer Perspective: An Overview"><h3>Post-Translational Modifications (PTMs), From A Cancer Perspective: An Overview</h3></a> 298 299 <p> 300 B Sharan Sharma<sup>1,2</sup>, Vaishna Prabhakaran [....] 301 </p> 302 <ul class="infolinks"> 303 304 <li><a href="https://www.oncogen.org/full-text/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview" target="_blank" title="Post-Translational Modifications (PTMs), From A Cancer Perspective: An Overview"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 305 306 307 308 <li> 309 <a href="https://www.oncogen.org/full-text/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview" target="_blank" title="Post-Translational Modifications (PTMs), From A Cancer Perspective: An Overview" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 310 </li> 311 312 313 314 315 </ul> 316 </div> 317 </div> 318 <div class="col-md-6"> 319 <div class="journalarticles fix_height"> 320 <div class="btn btn-sm btn-default m-b-10">Case Report</div> 321 322 <a href="https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma" target="_blank" title="Cognitive Impairment Secondary To Treatment Of Cured Brain Metastases Of Triple-Negative Breast Carcinoma"><h3>Cognitive Impairment Secondary To Treatment Of Cured Brain Metastases Of Triple-Negative Breast Carcinoma</h3></a> 323 324 <p> 325 Elise F Nassif*, Alexandre Arsene-Henry, Youlia M [....] 326 </p> 327 <ul class="infolinks"> 328 329 <li><a href="https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma" target="_blank" title="Cognitive Impairment Secondary To Treatment Of Cured Brain Metastases Of Triple-Negative Breast Carcinoma"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 330 331 332 333 <li> 334 <a href="https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma" target="_blank" title="Cognitive Impairment Secondary To Treatment Of Cured Brain Metastases Of Triple-Negative Breast Carcinoma" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 335 </li> 336 337 338 339 340 </ul> 341 </div> 342 </div> 343 <div class="col-md-6"> 344 <div class="journalarticles fix_height"> 345 <div class="btn btn-sm btn-default m-b-10">Review Article</div> 346 347 <a href="https://www.oncogen.org/full-text/single-subject-studies-in-prostate-cancer-how-graphing-psa-test-results-and-testosterone-levels-using-process-behavior-and-celeration-charts-can-provide-insight-and-guide-clinical-decisions" target="_blank" title="Single Subject Studies In Prostate Cancer: How Graphing PSA Test Results And Testosterone Levels Using Process Behavior And Celeration Charts Can Provide Insight And Guide Clinical Decisions"><h3>Single Subject Studies In Prostate Cancer: How Graphing PSA Test Results And Testosterone Levels Using Process Behavior And Celeration Charts Can Provide Insight And Guide Clinical Decisions</h3></a> 348 349 <p> 350 Al Pfadt*­<sup>1</sup>, Donald J Wheeler<sup>2 [....] 351 </p> 352 <ul class="infolinks"> 353 354 <li><a href="https://www.oncogen.org/full-text/single-subject-studies-in-prostate-cancer-how-graphing-psa-test-results-and-testosterone-levels-using-process-behavior-and-celeration-charts-can-provide-insight-and-guide-clinical-decisions" target="_blank" title="Single Subject Studies In Prostate Cancer: How Graphing PSA Test Results And Testosterone Levels Using Process Behavior And Celeration Charts Can Provide Insight And Guide Clinical Decisions"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 355 356 357 358 <li> 359 <a href="https://www.oncogen.org/full-text/single-subject-studies-in-prostate-cancer-how-graphing-psa-test-results-and-testosterone-levels-using-process-behavior-and-celeration-charts-can-provide-insight-and-guide-clinical-decisions" target="_blank" title="Single Subject Studies In Prostate Cancer: How Graphing PSA Test Results And Testosterone Levels Using Process Behavior And Celeration Charts Can Provide Insight And Guide Clinical Decisions" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 360 </li> 361 362 363 364 365 </ul> 366 </div> 367 </div> 368 <div class="col-md-6"> 369 <div class="journalarticles fix_height"> 370 <div class="btn btn-sm btn-default m-b-10">Research Article</div> 371 372 <a href="https://www.oncogen.org/full-text/a-clinical-study-of-biomarkers-to-predict-the-efficacy-of-cancer-immunotherapy-with-subcutaneous-low-dose-il-2-or-with-immune-checkpoint-inhibitors" target="_blank" title="A Clinical Study Of Biomarkers To Predict The Efficacy Of Cancer Immunotherapy With Subcutaneous Low-Dose Il-2 Or With Immune Checkpoint Inhibitors"><h3>A Clinical Study Of Biomarkers To Predict The Efficacy Of Cancer Immunotherapy With Subcutaneous Low-Dose Il-2 Or With Immune Checkpoint Inhibitors</h3></a> 373 374 <p> 375 Lissoni P*, Brivio F, Messina G, Vigore L, Rovelli [....] 376 </p> 377 <ul class="infolinks"> 378 379 <li><a href="https://www.oncogen.org/full-text/a-clinical-study-of-biomarkers-to-predict-the-efficacy-of-cancer-immunotherapy-with-subcutaneous-low-dose-il-2-or-with-immune-checkpoint-inhibitors" target="_blank" title="A Clinical Study Of Biomarkers To Predict The Efficacy Of Cancer Immunotherapy With Subcutaneous Low-Dose Il-2 Or With Immune Checkpoint Inhibitors"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 380 381 382 383 <li> 384 <a href="https://www.oncogen.org/full-text/a-clinical-study-of-biomarkers-to-predict-the-efficacy-of-cancer-immunotherapy-with-subcutaneous-low-dose-il-2-or-with-immune-checkpoint-inhibitors" target="_blank" title="A Clinical Study Of Biomarkers To Predict The Efficacy Of Cancer Immunotherapy With Subcutaneous Low-Dose Il-2 Or With Immune Checkpoint Inhibitors" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 385 </li> 386 387 388 389 390 </ul> 391 </div> 392 </div> 393 <div class="col-md-6"> 394 <div class="journalarticles fix_height"> 395 <div class="btn btn-sm btn-default m-b-10">Research Article</div> 396 397 <a href="https://www.oncogen.org/full-text/tumor-infiltrating-lymphocytes-expression-in-stage-iiic-iv-of-high-grade-serous-ovarian-cancer-variation-with-neoadjuvant-chemotherapy-and-prognostic-value" target="_blank" title="Tumor-Infiltrating Lymphocytes Expression In Stage IIIc/IV Of High-Grade Serous Ovarian Cancer: Variation With Neoadjuvant Chemotherapy And Prognostic Value"><h3>
397Tumor-Infiltrating Lymphocytes Expression In Stage IIIc/IV Of High-Grade Serous Ovarian Cancer: Variation With Neoadjuvant Chemotherapy And Prognostic Value</h3></a> 398 399 <p> 400 K Rojas*<sup>1</sup>, G Prado-Vazquez<sup>2</sup>, [....] 401 </p> 402 <ul class="infolinks"> 403 404 <li><a href="https://www.oncogen.org/full-text/tumor-infiltrating-lymphocytes-expression-in-stage-iiic-iv-of-high-grade-serous-ovarian-cancer-variation-with-neoadjuvant-chemotherapy-and-prognostic-value" target="_blank" title="Tumor-Infiltrating Lymphocytes Expression In Stage IIIc/IV Of High-Grade Serous Ovarian Cancer: Variation With Neoadjuvant Chemotherapy And Prognostic Value"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 405 406 407 408 <li> 409 <a href="https://www.oncogen.org/full-text/tumor-infiltrating-lymphocytes-expression-in-stage-iiic-iv-of-high-grade-serous-ovarian-cancer-variation-with-neoadjuvant-chemotherapy-and-prognostic-value" target="_blank" title="Tumor-Infiltrating Lymphocytes Expression In Stage IIIc/IV Of High-Grade Serous Ovarian Cancer: Variation With Neoadjuvant Chemotherapy And Prognostic Value" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 410 </li> 411 412 413 414 415 </ul> 416 </div> 417 </div> 418 <div class="col-md-6"> 419 <div class="journalarticles fix_height"> 420 <div class="btn btn-sm btn-default m-b-10">Opinion Article</div> 421 422 <a href="https://www.oncogen.org/full-text/triple-hormonal-blockade-adt3-a-patient-s-perspective" target="_blank" title="Triple Hormonal Blockade (ADT3): A Patientâs Perspective"><h3>Triple Hormonal Blockade (ADT3): A Patientâs Perspective</h3></a> 423 424 <p> 425 Charles Maack*</p> 426 427 </p> 428 <ul class="infolinks"> 429 430 <li><a href="https://www.oncogen.org/full-text/triple-hormonal-blockade-adt3-a-patient-s-perspective" target="_blank" title="Triple Hormonal Blockade (ADT3): A Patientâs Perspective"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 431 432 433 434 <li> 435 <a href="https://www.oncogen.org/full-text/triple-hormonal-blockade-adt3-a-patient-s-perspective" target="_blank" title="Triple Hormonal Blockade (ADT3): A Patientâs Perspective" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 436 </li> 437 438 439 440 441 </ul> 442 </div> 443 </div> 444 <div class="col-md-6"> 445 <div class="journalarticles fix_height"> 446 <div class="btn btn-sm btn-default m-b-10">Research Article</div> 447 448 <a href="https://www.oncogen.org/full-text/removal-of-carcinogenic-arsenic-from-drinking-water-by-the-application-of-ion-exchange-resins" target="_blank" title="Removal Of Carcinogenic Arsenic From Drinking Water By The Application Of Ion Exchange Resins"><h3>Removal Of Carcinogenic Arsenic From Drinking Water By The Application Of Ion Exchange Resins</h3></a> 449 450 <p> 451 Sevtap Karakurt<sup>1</sup>, Erol Pehlivan<sup>1</ [....] 452 </p> 453 <ul class="infolinks"> 454 455 <li><a href="https://www.oncogen.org/full-text/removal-of-carcinogenic-arsenic-from-drinking-water-by-the-application-of-ion-exchange-resins" target="_blank" title="Removal Of Carcinogenic Arsenic From Drinking Water By The Application Of Ion Exchange Resins"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 456 457 458 459 <li> 460 <a href="https://www.oncogen.org/full-text/removal-of-carcinogenic-arsenic-from-drinking-water-by-the-application-of-ion-exchange-resins" target="_blank" title="Removal Of Carcinogenic Arsenic From Drinking Water By The Application Of Ion Exchange Resins" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 461 </li> 462 463 464 465 466 </ul> 467 </div> 468 </div> 469 <div class="col-md-6"> 470 <div class="journalarticles fix_height"> 471 <div class="btn btn-sm btn-default m-b-10">Case Report</div> 472 473 <a href="https://www.oncogen.org/full-text/breast-metachronous-carcinoma-and-sarcoma-in-a-young-patient-leading-to-the-diagnosis-of-li-fraumeni-syndrome" target="_blank" title="Breast Metachronous Carcinoma and
473Sarcoma in a Young Patient Leading to the Diagnosis of Li Fraumeni Syndrome"><h3>Breast Metachronous Carcinoma and Sarcoma in a Young Patient Leading to the Diagnosis of Li Fraumeni Syndrome</h3></a> 474 475 <p> 476 Seidler SJ and Huber DE</p> 477 478 </p> 479 <ul class="infolinks"> 480 481 <li><a href="https://www.oncogen.org/full-text/breast-metachronous-carcinoma-and-sarcoma-in-a-young-patient-leading-to-the-diagnosis-of-li-fraumeni-syndrome" target="_blank" title="Breast Metachronous Carcinoma and Sarcoma in a Young Patient Leading to the Diagnosis of Li Fraumeni Syndrome"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 482 483 484 485 <li> 486 <a href="https://www.oncogen.org/full-text/breast-metachronous-carcinoma-and-sarcoma-in-a-young-patient-leading-to-the-diagnosis-of-li-fraumeni-syndrome" target="_blank" title="Breast Metachronous Carcinoma and Sarcoma in a Young Patient Leading to the Diagnosis of Li Fraumeni Syndrome" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 487 </li> 488 489 490 491 492 </ul> 493 </div> 494 </div> 495 <div class="col-md-6"> 496 <div class="journalarticles fix_height"> 497 <div class="btn btn-sm btn-default m-b-10">Case Report</div> 498 499 <a href="https://www.oncogen.org/full-text/hearing-loss-tinnitus-and-pineal-germinoma-parinaud-dorsal-midbrain-syndrome-revisited" target="_blank" title="Hearing Loss, Tinnitus And Pineal Germinoma: Parinaud Dorsal Midbrain Syndrome Revisited"><h3>Hearing Loss, Tinnitus And Pineal Germinoma: Parinaud Dorsal Midbrain Syndrome Revisited</h3></a> 500 501 <p> 502 Rithvik Marri<sup>1</sup>, Harini Rao<sup>2</sup>, [....] 503 </p> 504 <ul class="infolinks"> 505 506 <li><a href="https://www.oncogen.org/full-text/hearing-loss-tinnitus-and-pineal-germinoma-parinaud-dorsal-midbrain-syndrome-revisited" target="_blank" title="Hearing Loss, Tinnitus And Pineal Germinoma: Parinaud Dorsal Midbrain Syndrome Revisited"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 507 508 509 510 <li> 511 <a href="https://www.oncogen.org/full-text/hearing-loss-tinnitus-and-pineal-germinoma-parinaud-dorsal-midbrain-syndrome-revisited" target="_blank" title="Hearing Loss, Tinnitus And Pineal Germinoma: Parinaud Dorsal Midbrain Syndrome Revisited" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 512 </li> 513 514 515 516 517 </ul> 518 </div> 519 </div> 520 <div class="col-md-6"> 521 <div class="journalarticles fix_height"> 522 <div class="btn btn-sm btn-default m-b-10">Research Article</div> 523 524 <a href="https://www.oncogen.org/full-text/chromatographic-fractionation-of-an-ethanolic-extract-of-peels-from-ipomoea-batatas-lam-for-improved-anticancer-activity" target="_blank" title="Chromatographic Fractionation of An Ethanolic Extract of Peels from Ipomoea batatas Lam for Improved Anticancer Activity"><h3>Chromatographic Fractionation of An Ethanolic Extract of Peels from Ipomoea batatas Lam for Improved Anticancer Activity</h3></a> 525 526 <p> 527 Oluyori Abimbola P.<sup>1*</sup>, Olatunji Gabriel [....] 528 </p> 529 <ul class="infolinks"> 530 531 <li><a href="https://www.oncogen.org/full-text/chromatographic-fractionation-of-an-ethanolic-extract-of-peels-from-ipomoea-batatas-lam-for-improved-anticancer-activity" target="_blank" title="Chromatographic Fractionation of An Ethanolic Extract of Peels from Ipomoea batatas Lam for Improved Anticancer Activity"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 532 533 534 535 <li> 536 <a href="https://www.oncogen.org/full-text/chromatographic-fractionation-of-an-ethanolic-extract-of-peels-from-ipomoea-batatas-lam-for-improved-anticancer-activity" target="_blank" title="Chromatographic Fractionation of An Ethanolic Extract of Peels from Ipomoea batatas Lam for Improved Anticancer Activity" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 537 </li> 538 539 540 541 542 </ul> 543 </div> 544 </div> 545 <div class="col-md-6"> 546 <div class="journalarticles fix_height"> 547 <div class="btn btn-sm btn-default m-b-10">Case Report</div> 548 549 <a href="https://www.oncogen.org/full-text/primary-renal-lymphoma-a-case-report" target="_blank" title="Primary Renal Lymphoma: A Case Report"><h3>Primary Renal Lymphoma: A Case Report</h3></a> 550 551 <p> 552 Mohammed Alagha<sup>1*</sup>, Ramadan Algamal<sup> [....] 553 </p> 554 <ul class="infolinks"> 555 556 <li><a href="https://www.oncogen.org/full-text/primary-renal-lymphoma-a-case-report" target="_blank" title="Primary Renal Lymphoma: A Case Report"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 557 558 559 560 <li> 561 <a href="https://www.oncogen.org/full-text/primary-renal-lymphoma-a-case-report" target="_blank" title="Primary Renal Lymphoma: A Case Report" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 562 </li> 563 564 565 566 567 </ul> 568 </div> 569 </div> 570 <div class="col-md-6"> 571 <div class="journalarticles fix_height"> 572 <div class="btn btn-sm btn-default m-b-10">Research Article</div> 573 574 <a href="https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma" target="_blank" title="The Importance of Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) and Raman Biospectroscopy of Single-Walled Carbon Nanotubes (SWCNT) and Multi-Walled Carbon Nanotubes (MWCNT) in Interpreting Infrared and Raman Spectra of Human Cancer Cells, Tissues and Tumors"><h3>The Importance of Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) and Raman Biospectroscopy of Single-Walled Carbon Nanotubes (SWCNT) and Multi-Walled Carbon Nanotubes (MWCNT) in Interpreting [....]</h3></a> 575 576 <p> 577 Elise F Nassif*, Alexandre Arsene-Henry, Youlia M [....] 578 </p> 579 <ul class="infolinks"> 580 581 <li><a href="https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma" target="_blank" title="The Importance of Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) and Raman Biospectroscopy of Single-Walled Carbon Nanotubes (SWCNT) and Multi-Walled Carbon Nanotubes (MWCNT) in Interpreting Infrared and Raman Spectra of Human Cancer Cells, Tissues and Tumors"><i class="fa fa-file-text" aria-hidden="true"></i>Full-Text</a></li> 582 583 584 585 <li> 586 <a href="https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma" target="_blank" title="The Importance of Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) and Raman Biospectroscopy of Single-Walled Carbon Nanotubes (SWCNT) and Multi-Walled Carbon Nanotubes (MWCNT) in Interpreting Infrared and Raman Spectra of Human Cancer Cells, Tissues and Tumors" ><i class="fa fa-file-pdf-o" aria-hidden="true"></i>PDF</a> 587 </li> 588 589 590 591 592 </ul> 593 </div> 594 </div> 595 596 597 598 </div> 599 <!-- articles end --> 600 601 602 </div> 603 604 605 </div> <!-- col-md-9 end --> 606 607 <!-- Right section --> 608 <!-- col-md-3 start --> 609 <div class="col-md-3"> 610 611 <!-- current issues start--> 612 <div class="journalarticlesheading m-t-40"> 613 <h3>Current Issues</h3>
614 </div> 615 <div class="currentissues m-t-20 m-b-40"> 616 617 <div class="currentissuescontent"> 618 <h4><a href="https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma" target="_blank" title="Cognitive Impairment Secondary To Treatment Of Cured Brain Metastases Of Triple-Negative Breast Carcinoma">Cognitive Impairment Secondary To Treatment Of Cured Brain Metastases Of Triple-Negative Breast Carcinoma</a></h4> 619 620 </div> 621 <div class="currentissuescontent"> 622 <h4><a href="https://www.oncogen.org/full-text/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview" target="_blank" title="Post-translational Modifications (PTMs), from a Cancer Perspective: An Overview">Post-translational Modifications (PTMs), from a Cancer Perspective: An Overview</a></h4> 623 624 </div> 625 <div class="currentissuescontent"> 626 <h4><a href="https://www.oncogen.org/full-text/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer" target="_blank" title="The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer">The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer</a></h4> 627 628 </div> 629 <div class="currentissuescontent"> 630 <h4><a href="https://www.oncogen.org/full-text/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy" target="_blank" title="Palliative Systemic Treatment of Advanced Merkel Cell Carcinoma in the Pre-Immunotherapy Era: A Retrospective, Single-Center Analysis of Patients with An Orphan Neuroendocrine Malignancy">Palliative Systemic Treatment of Advanced Merkel Cell Carcinoma in the Pre-Immunotherapy Era: A Retrospective, Single-Center Analysis of Patients with An Orphan Neuroendocrine Malignancy</a></h4> 631 632 </div> 633 <div class="currentissuescontent"> 634 <h4><a href="https://www.oncogen.org/full-text/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells" target="_blank" title="CRISPR/Cas9-based Editing of CDK4, p107, and TGFβ1 in Human Breast and Lung Cancer Cells">CRISPR/Cas9-based Editing of CDK4, p107, and TGFβ1 in Human Breast and Lung Cancer Cells</a></h4> 635 636 </div> 637 638 639 640 641 642 </div> 643 <!-- current issues end--> 644 645 <!-- latest tweets start--> 646 <!-- latest tweets start--> 647 <div class="journalarticlesheading"> 648 <h3>Latest Tweets</h3> 649 </div> 650 651 <div class="latesttweets m-t-20 m-b-40"> 652 <a class="twitter-timeline" data-theme="" data-height="600" data-link-color="" href="https://twitter.com/MagnusMedClub?ref_src=twsrc%5Etfw">Tweets by CatalysisEvent</a>
652<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
652 653 </div> 654 <!-- latest tweets end--> 655 656 657 658 659 660 <!-- Subscribe start--> 661 <div class="journalarticlesheading"> 662 <h3>Subscribe</h3> 663 </div> 664 <div class="Subscribe m-t-20"> 665 <h6>Subscribe to our email newsletter</h6> 666 667 <div class="subscribesec"> 668 669 670 <form class="widget-subscribe-form ram" id="subscribe_form" method="post" autocomplete="off"> 671 672 <div class="row"> 673 <div class="col-md-12"> 674 <div class="form-group"> 675 676 <label class="upper text-left" for="name"> Email address: </label> 677 <label for="subscribe_email" class="error" id="subscribe_email-error" style="display:none;"> </label> 678 <input type="email" aria-required="true" name="subscribe_email" class="required email" placeholder="Enter your Email"> 679 </div> 680 </div> 681 </div> 682 683 684 685 <div class="row"> 686 <div class="col-md-12"> 687 <div class="form-group"> 688 <label class="upper text-left" for="name"> Enter Captcha: </label> 689 <input type="text" class="form-control required" name="sub_captchcode" placeholder="Enter Answer" id="sub_captchcode" aria-required="true"> 690 </div> 691 </div> 692 </div> 693 694 <div class="row"> 695 <div class="col-md-12" id="cap-img"> 696 <div class="form-group"> 697 <label class="upper text-left" for="name"> Captcha Code: </label> 698 <div class="clear"> 699 <div class="pull-left"> 700 <img src="" class="captcha-img" alt="Antispam Code"> 701 </div> 702 <div class="pull-left"> 703 <a title="reload" class="reload-captcha" href="javascript:relod();" > 704 <i class="fa fa-refresh fa-3" aria-hidden="true"></i> 705 </a> 706 </div> 707 <a title="reload" class="reload-captcha" href="javascript:relod();" >Generate new code</a> 708 </div> 709 </div> 710 </div> 711 </div> 712 713 714 <div class="row"> 715 <div class="col-md-12"> 716 <button class="btn btn-lg btn-full" type="submit">Subscribe</button> 717 </div> 718 </div> 719 720 </form>
721 </div> 722 </div> 723 724 725 <!-- Subscribe end--> 726 727 728 729 </div> 730 <!-- col-md-3 end --> 731 732 733 </div> 734 </div> 735 <!--end container end--> 736 737 738 739 740 741 <div class="footer"> 742 <div class="container"> 743 <div class="row"> 744 <div class="col-md-4 footersupport"> 745 <div class="m-b-40"> 746 <h3>Address</h3> 747 <p><i class="fa fa-university" aria-hidden="true"></i><strong>Magnus Med Club</strong></p> 748 <p><i class="fa fa-map-marker" aria-hidden="true"></i> 8408 Gradington Drive, 749 <br>Westerville, OH 43081, USA</p> 750 <p><i class="fa fa-phone" aria-hidden="true"></i>+1 614-826-7766</p> 751 <p><i class="fa fa-envelope" aria-hidden="true"></i><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="2e4d41405a4f4d5a6e434f49405b5d434b4a4d425b4c004d4143">[email protected]</a></p> 752 </div> 753 <div class=""> 754 <h4>Stay Connected</h4> 755 <div class="socialmedia1"> 756 <ul> 757 <li> 758 <a href="https://www.facebook.com" title="Face Book" target="_blank"><div class="facebook"> 759 <i class="fa fa-facebook" aria-hidden="true"></i><br> 760 </div></a> 761 </li> 762 <li> 763 <a href="https://x.com/magnus_med1203" title="Twitter" target="_blank"><div class="twitter"> 764 <i class="fa fa-twitter" aria-hidden="true"></i><br> 765 </div></a> 766 </li> 767 <li> 768 <a href="https://plus.google.com/" title="Google+" target="_blank"><div class="googleplus"> 769 <i class="fa fa-google" aria-hidden="true"></i><br> 770 </div></a> 771 </li> 772 <li> 773 <a href="https://www.magnusmedclub.com/" title="RSS Feeds" target="_blank"><div class="rss"> 774 <i class="fa fa-rss" aria-hidden="true"></i><br> 775 </div></a> 776 </li> 777 </ul> 778 </div> 779 </div> 780 </div> 781 782 <div class="col-md-4 footersupport"> 783 784 785 <h4>Quick Links</h4> 786 <div class="row"> 787 788 789 <div class="col-md-12 col-xs-12"> 790 <ul> 791 <li><a href="https://www.magnusmedclub.com/plagarism#pl4" title="Peer-Review Process" target="_blank" >Peer-Review Process</a></li> 792 793 <li><a href="https://www.magnusmedclub.com/plagarism#pl5" title="Article Process Charges" target="_blank" >Article Process Charges</a></li> 794 795 <li><a href="https://www.magnusmedclub.com/plagarism#pl1" title="Plagarism" target="_blank" >Plagarism</a></li> 796 797 <li><a href="https://www.magnusmedclub.com/plagarism#pl2" title="Open Access Policy" target="_blank" >Open Access Policy</a></li> 798 799 <li><a href="https://www.magnusmedclub.com/plagarism#pl3" title="Publication Ethics" target="_blank" >Publication Ethics</a></li> 800 801 </ul> 802 </div> 803 </div> 804 </div> 805 806 <div class="col-md-4 footersupport"> 807 <h3>Quick Contact</h3> 808 <form class="widget-subscribe-form" id="signup_form" method="post"> 809 <div class="row"> 810 <div class="col-md-6"> 811 <div class="form-group"> 812 <label class="text-white">Name</label> 813 <input type="text" aria-required="true" name="q_name" class="form-control required" placeholder="Name"> 814 </div> 815 </div> 816 817 <div class="col-md-6"> 818 <div class="form-group"> 819 <label class="text-white">Email address</label> 820 <input type="email" aria-required="true" name="q_email" class="form-control required" placeholder="Your Email address"> 821 </div> 822 </div> 823 </div> 824 825 <div class="row"> 826 <div class="col-md-12"> 827 <div class="form-group"> 828 <label for="" class="text-white">Message</label> 829 <textarea class="form-control" name="q_message" rows="2" placeholder="Message"></textarea> 830 </div> 831 </div> 832 </div> 833 834 835 836 <div class="row"> 837 838 <div class="col-md-6"> 839 <div class="form-group"> 840 <label class="text-white" for="captchcode_sign">Enter Captcha <span class="span">*</span>: </label> 841 <input type="text" class="form-control required" name="captchcode_q" placeholder="Enter Captch Code" id="captchcode_q" aria-required="true"> 842 <label for="captchcode_q" class="error" id="captchcode_q-error" style="display:none;"></label> 843 </div> 844 </div> 845 <div class="col-md-6"> 846 <div class="form-group"> 847 <label class="text-white" >Captcha Code: </label> 848 <div class="cpatcha-box-1"> 849 <div class="pull-left"> 850 <img src="https://magnusmedclub.com/assets-front/img/captch-img.jpg" class="captcha-img" alt="Antispam Code"> 851 </div> 852 <div class="pull-left"> 853 <a title="reload" class="reload-captcha" href="javascript:relod();" > 854 <i class="fa fa-refresh fa-2" aria-hidden="true"></i> 855 </a> 856 </div>
857 <span> <a title="reload" href="javascript:relod();" class="text-white">genrate new code</a> </span> 858 </div> 859 </div> 860 </div> 861 </div> 862 863 864 <button class="btn btn-lg btn-full" type="submit">Submit</button> 865 866 </form> 867 <div class="m-t-0 m-l-10 m-r-10 center"> 868 <div class="col-md-12" id="q_success"></div> 869 </div> 870 </div> 871 </div> 872 <!-- <hr> 873 <p>Copyright © 2018 Magnus Med Club Ltd. All rights reserved.</p> --> 874 </div> 875 </div> 876 877 <div class="footerbottom"> 878 <div class="container"> 879 <div class="row"> 880 <div class="col-md-12"> 881 882 <p>© Copyright 2018 Magnus Med Club Ltd. All Rights Reserved. </p> 883 </div> 884 </div> 885 </div> 886 </div> 887 888 <div class='scrolltop'> 889 <div class='scroll icon'><i class="fa fa-4x fa-angle-up"></i></div> 890</div> 891 892 893<a href="javascript:avoid;" rel="nofollow" id="goToTop" class="cd-top js-cd-top cd-top--fade-out cd-top--show"><i class="fa fa-angle-up"></i></a> 894 <!-- Go to top button --> 895 896 897 <!--Plugins-->
vendor: 114 bytes, lines 897-898
897 898 <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script>
898<script src="https://magnusmedclub.com/assets-front/js/jquery.js"></script>
898 899
899<script src="https://magnusmedclub.com/assets-front/js/plugins.js"></script>
899 900 <!--Template functions--> 901
901<script src="https://magnusmedclub.com/assets-front/js/functions.js"></script>
901 902 903 904 <!-- Live Chat functions-->
905<script type="text/javascript">function add_chatinline(){var hccid=93006337;var nt=document.createElement("script");nt.async=true;nt.src="https://mylivechat.com/chatinline.aspx?hccid="+hccid;var ct=document.getElementsByTagName("script")[0];ct.parentNode.insertBefore(nt,ct);} 906 907add_chatinline(); </script>
907 908 909 <!-- WhatsUp functions--> 910 <!--
910<script src="https://app.wabi-app.com/widget/js/wabi.js?phone_number=+15407091879&lang=en&position=left"></script>
910--> 911 912 913 914 915 916
917<script> 918 $("#subscribe_form").submit(function(){ 919 920 var data=$(this).serialize(); 921 $.ajax({ 922 type: 'POST', 923 url: "https://magnusmedclub.com/subscribers", 924 data: data, 925 dataType: 'json', 926 beforeSend: function() { 927 928 // setting a timeout 929 // $(placeholder).addClass('loading'); 930 }, 931 success: function(msg) { 932 //alert(); 933 //console.log('Data:', msg); 934 935 if(msg['status']=='error'){ 936 $("#subscribe_email-error").fadeIn(); 937 $("#subscribe_email-error").html(msg['msg']) ; 938 }else{ 939 $("#subscribe_email-error").fadeIn(); 940 $("#subscribe_form")[0].reset(); 941 $("#subscribe_email-error").removeClass('error'); 942 $("#subscribe_email-error").html(msg['msg']) ; 943 $("#subscribe_email-error").fadeOut(6000); 944 } 945 946 }, 947 948 949 }); 950 return false; 951 952 }); 953 954 955 956 957 958$("#signup_form").submit(function(){ 959 960 var data=$(this).serialize(); 961 $.ajax({ 962 type: 'POST', 963 url: "https://magnusmedclub.com/quickcontact", 964 data: data, 965 dataType: 'json', 966 beforeSend: function(msg) { 967 //console.log('Data:', msg); 968 // setting a timeout 969 // $(placeholder).addClass('loading'); 970 }, 971 success: function(msg) { 972 973 //console.log('Data:', msg); 974 var mid=msg['id']; 975 var id='#'+mid+'-error'; 976 if(msg['status']=='error'){ 977 $(id).show(); 978 $(id).html(msg['msg']) ; 979 $("input[name="+mid+"]").focus(); 980 }else{ 981 $("#"+mid).fadeIn(); 982 $("#signup_form")[0].reset(); 983 $("#"+mid).html(msg['msg']) ; 984 $("#"+mid).fadeOut(6000); 985 } 986 987 }, 988 989 990 }); 991 return false; 992 993 }); 994 995 </script>
995 996 997
997<script src="https://magnusmedclub.com/assets-admin/js/plugins/jquery.validate.min.js" type="text/javascript"></script>
997 998
998<script type="text/javascript"> 999 function setFormValidation(id) { 1000 $(id).validate({ 1001 highlight: function(element) { 1002 $(element).closest('.form-group').removeClass('has-success').addClass('has-error'); 1003 $(element).closest('.form-check').removeClass('has-success').addClass('has-error'); 1004 }, 1005 success: function(element) { 1006 $(element).closest('.form-group').removeClass('has-error').addClass('has-success'); 1007 $(element).closest('.form-check').removeClass('has-error').addClass('has-success'); 1008 }, 1009 errorPlacement: function(error, element) { 1010 $(element).closest('.form-group').append(error).addClass('has-error'); 1011 }, 1012 }); 1013 } 1014 1015 $(document).ready(function() { 1016 1017 setFormValidation('#signup_form'); 1018 1019 }); 1020</script>
1020 1021
1022<script> 1023$(function(){ 1024 relod(); 1025 1026}); 1027 1028 function relod(){ 1029 //alert(); 1030 $.ajax({ 1031 url:'https://magnusmedclub.com/new-captcha', 1032 success:function(data){ 1033 $('.captcha-img').attr('src', data); 1034 } 1035 }); 1036 } 1037</script>
1037 1038
1039<script type="module" src="https://static.cloudflareinsights.com/beacon.min.js/v4bc70e2c01a94c73b74392e4234840661791215815920" integrity="sha512-L0ha0OXavK/8okipN9F8BtP84dg9DUhPERbBXzwI6dgTA55d2+yweo3pn5CSFYs45/r8md2+xvUPtTdvTNRfjA==" data-cf-beacon='{"version":"2024.11.0","token":"5d191fcba85540908275da72fc03ef9c","r":1,"spa":2}' crossorigin="anonymous"></script>
1039 1040</body> 1041</html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.